A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Hervé Dombret(University of London Institute in Paris), Jörge E. Cortes(Augusta University Health), Bruno Lioure, Pierre Bories, Stella K. Kim(Robert Cizik Eye Clinic), Thibaut Leguay(Centre Hospitalier Universitaire de Bordeaux), Corina Oprea(Sanofi (France)), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Xavier Thomas(Hôpital Lyon Sud), Martine Escoffre‐Barbe(Université Rennes 2), Ehab Atallah(Medical College of Wisconsin), Susan O’Brien(University of California, Irvine), Kevin Kelly(The University of Texas at San Antonio Health Science Center), Jean-Pierre Marolleau(Centre Hospitalier Universitaire Amiens-Picardie), Laurence Hatteville(Sanofi (France))
Cited by 67
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k